Johnson & Johnson Vision: Surgical Vision Announces Activities at ESCRS |
| Advertisement |
 
|
Johnson & Johnson Vision: Surgical Vision has announced in a press release that it will be presenting new data and participating in a series of events at the upcoming 40th European Society of Cataract and Refractive Surgeons (ESCRS) Congress. The activities will include a comparison of rotational stability between Zeiss AT Lisa 939 and Synergy Toric II for correction of anisometropia with astigmatism and presbyopia; participation in I-Novation sessions on sustainability, presbyopia, and cataract extraction; and an IME Symposium on presbyopia IOLs. More information can be found at https://www.prnewswire.co.uk/news-releases/johnson-amp-johnson-vision-surgical-vision-announces-new-data-and-sustainability-activities-at-european-society-of-cataract-and-refractive-surgeons-congress-804564118.html.
|
Eyenovia to Participate at September Conferences |
| Eyenovia has announced in a press release that it will be participating in multiple medical meetings in September. The meetings include the Ophthalmology Futures European Forum 2022; The T.H.E. Summit by Treehouse Eyes; The 40th Congress of the European Society of Cataract and Refractive Surgeons (ESCRS) 2022; and Eyecelerator at AAO 2022. The presentations will discuss microdose delivery and Eyenovia’s Optejet dispenser. More information can be found at https://www.globenewswire.com/news-release/2022/09/06/2510331/0/en/Eyenovia-to-Participate-in-Multiple-Medical-Meetings-in-September.html.
|
Ocuphire to Present at H.C. Wainwright Conference |
| Ocuphire Pharma has announced in a press release that founder and CEO Mina Sooch, MBA, will present a corporate overview at the H.C. Wainwright 24th Annual Global Investment Conference. The on-demand session will be available on September 12. More information can be found at https://www.benzinga.com/pressreleases/22/09/g28755872/ocuphire-pharma-to-present-at-the-h-c-wainwright-24th-annual-global-investment-conference.
|
Visus to Present at Baird 2022 Global Healthcare Conference |
| Visus Therapeutics, a company developing novel, pupil-modulating therapeutics designed to correct the loss of near vision associated with presbyopia, has announced in a press release that co-founder and CEO Ben Bergo will present at the Baird 2022 Global Healthcare Conference. The presentation is scheduled for September 13th, and Mr. Bergo will be available for one-on-one investor meetings that day. The company presentation will be available on Visus' website. More information can be found at https://www.businesswire.com/news/home/20220907005672/en/Visus-Therapeutics-to-Present-at-the-Baird-2022-Global-Healthcare-Conference.
|
Lento Bio Raises $680,000 in Oversubscribed Seed Round |
| Lento Bio, a preclinical pharmaceutical company developing small-molecule therapeutics to restore ocular lens flexibility and near vision in presbyopia patients, has announced in a press release they have raised $680,000 in funding during their recent oversubscribed seed round. The lead investor for the round is Ichor Life Sciences, which provided $400,000 in funding. The seed round will be used to conduct research and testing that will establish proof of concept for Lento Bio's therapeutics and help optimize lead compounds in early-stage pre-clinical studies. More information can be found at https://www.accesswire.com/714772/Lento-Bio-Raises-680000-in-Oversubscribed-Seed-Round-Led-by-Ichor-Life-Sciences.
|
